A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Isha MolYannan HuThomas William LeBlancJoseph C CappelleriHaitao ChuGuido NadorDidem AydinAlex SchepartPatrick HlavacekPublished in: Current medical research and opinion (2023)
In the MAIC, elranatamab was consistently associated with improved rates and depth of response and significantly longer PFS and OS versus PCT in LocoMMotion and MAMMOTH.